Company Description
ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines for neurodegenerative diseases and other misfolded protein diseases in Canada.
The company’s proprietary discovery platform comprises ProMIS, which enables drug discovery through a combination of protein biology, physics, and supercomputing.
Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers for treating Alzheimer's disease; PMN267 for the treatment of amyotrophic lateral sclerosis; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils for treating multiple system atrophy.
The company also develops PNM440, an alpha-synuclein vaccine for treating multiple synucleinopathies; and PMN311, an amyloid-beta vaccine for the treatment of Alzheimer's.
In addition, it is developing therapies for frontotemporal lobar degeneration, Huntington’s disease, progressive supranuclear palsy, corticobasal degeneration, and schizophrenia.
The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015.
ProMIS Neurosciences, Inc. is headquartered in Toronto, Canada.
| Country | Canada |
| Founded | 2004 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 11 |
| CEO | Neil Warma |
Contact Details
Address: 1920 Yonge Street, Suite 200 Toronto, ON M4S 3E2 Canada | |
| Phone | 416 847 6898 |
| Website | promisneurosciences.com |
Stock Details
| Ticker Symbol | PMN |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 1374339 |
| CUSIP Number | 74346M406 |
| ISIN Number | CA74346M5054 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Neil K. Warma M.B.A. | Chief Executive Officer, President, Compliance Officer and Director |
| Eugene W. Williams | Co-Founder and Chairman |
| Dr. Neil R. Cashman M.D. | Co-Founder, Co-Chairman of Scientific Advisory Board, Chief Scientific Officer and Director |
| Dr. Johanne Kaplan Ph.D. | Chief Development Officer |
| Dr. Larry Douglas Altstiel M.D., Ph.D. | Chief Medical Officer |
| Daniel E. Geffken M.B.A. | Chief Financial Officer |
| Dr. David Wishart Ph.D. | Chief Physics Officer |
| Dennis Chen Ph.D. | Head of Manufacturing and Senior Consultant |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 15, 2026 | SCHEDULE 13G | Filing |
| May 15, 2026 | SCHEDULE 13G | Filing |
| May 12, 2026 | 10-Q | Quarterly Report |
| May 12, 2026 | 8-K | Current Report |
| May 7, 2026 | SCHEDULE 13G/A | Filing |
| Apr 9, 2026 | ARS | Filing |
| Apr 9, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 9, 2026 | DEF 14A | Other definitive proxy statements |
| Apr 7, 2026 | SCHEDULE 13G | Filing |
| Apr 2, 2026 | EFFECT | Notice of Effectiveness |